Namiki Izumi

Summary

Affiliation: Japanese Red Cross
Country: Japan

Publications

  1. ncbi request reprint Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
    Namiki Izumi
    Musashino Red Cross Hospital, Tokyo, Japan
    J Gastroenterol 49:941-53. 2014
  2. pmc Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Kyonancho 1 26 1, Musashinoshi, 180 8610 Tokyo, Japan
    Hepat Res Treat 2010:703602. 2010
  3. ncbi request reprint Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Namiki Izumi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Intervirology 48:59-63. 2005
  4. ncbi request reprint A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load
    Namiki Izumi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Intervirology 47:102-7. 2004
  5. pmc Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan
    J Gastroenterol 48:382-90. 2013
  6. pmc Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
    Hidenori Toyoda
    Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan
    BMC Infect Dis 12:324. 2012
  7. doi request reprint α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan
    Hepatology 58:1253-62. 2013
  8. ncbi request reprint Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    J Hepatol 43:623-9. 2005
  9. doi request reprint Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Gastroenterology 134:1396-405. 2008
  10. doi request reprint Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Hepatology 55:20-9. 2012

Collaborators

Detail Information

Publications69

  1. ncbi request reprint Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
    Namiki Izumi
    Musashino Red Cross Hospital, Tokyo, Japan
    J Gastroenterol 49:941-53. 2014
    ..Two Phase III, open-label trials in Japan investigated efficacy and safety of simeprevir and peginterferon-α-2a/ribavirin (PR) combination therapy in treatment-experienced patients with genotype 1 HCV infection...
  2. pmc Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Kyonancho 1 26 1, Musashinoshi, 180 8610 Tokyo, Japan
    Hepat Res Treat 2010:703602. 2010
    ..Since new anti-HCV agents are under development, it will be necessary in the future to select the patients who have a high possibility of achieving SVR if treatment is performed with standard regimen...
  3. ncbi request reprint Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Namiki Izumi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Intervirology 48:59-63. 2005
    ..The aim of this study is to investigate the risk factors for the development of HCC after IFN in chronic hepatitis C as well as whether the incidence of HCC will be reduced by ribavirin and IFN combination therapy or not...
  4. ncbi request reprint A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load
    Namiki Izumi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Intervirology 47:102-7. 2004
    ..Viral dynamics have been utilized for the evaluation of antiviral effects, especially the exponential second decay slope, which represents the elimination of infected cells...
  5. pmc Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan
    J Gastroenterol 48:382-90. 2013
    ..We investigated whether the administration of maintenance doses of interferon prevented hepatocellular carcinoma (HCC) in patients with chronic hepatitis C...
  6. pmc Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
    Hidenori Toyoda
    Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan
    BMC Infect Dis 12:324. 2012
    ..We conducted a multicenter study to validate this importance along with baseline predictive factors in this patient subpopulation...
  7. doi request reprint α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan
    Hepatology 58:1253-62. 2013
    ..Measurement of these values is useful for predicting future HCC risk after IFN treatment. Suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication...
  8. ncbi request reprint Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    J Hepatol 43:623-9. 2005
    ..To elucidate whether ribavirin acts as a mutagen in the clinical setting and to clarify the relationship between ribavirin-induced mutations and virological response to combined therapy...
  9. doi request reprint Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Gastroenterology 134:1396-405. 2008
    ..The aim is to elucidate the mechanisms underlying resistance to antiviral therapy and predictive usefulness of gene quantification in chronic hepatitis C (CH-C)...
  10. doi request reprint Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Hepatology 55:20-9. 2012
    ..IPS-1 down-regulation in IL28B minor patients was confirmed by western blotting, and the extent of IPS-1 protein cleavage was associated with the variable treatment response...
  11. doi request reprint Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Antivir Ther 17:35-43. 2012
    ..This study aimed to define factors associated with relapse among responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in chronic hepatitis C...
  12. doi request reprint Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact
    Tohru Utsunomiya
    Department of Surgery, The University of Tokushima, Japan Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Japan Department of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Japan Department of Radiology, Kanazawa University Graduate School of Medical Science, Japan Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan Department of Biostatistics, School of Public Health, University of Tokyo, Japan Department of Pathology, Keio University School of Medicine, Japan Department of Clinical Laboratory Medicine, Kurume University Hospital, Japan Department of Surgery, Kobe University Graduate School of Medicine, Japan Department of Hepatobiliary and Pancreatic Surgery, University of Tokyo Graduate School of Medicine, Japan and Department of Surgery, Japanese Red Cross Medical Center, Japan
    Ann Surg 259:336-45. 2014
    ....
  13. doi request reprint Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Naoki Hiramatsu
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
    J Gastroenterol 46:1111-9. 2011
    ..This study aimed to develop a model to predict the development of severe anemia during pegylated interferon alpha-2b plus ribavirin combination therapy...
  14. doi request reprint Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino, Tokyo 180 8610, Japan
    J Gastroenterol 46:401-9. 2011
    ..This study aimed to develop a model for the pre-treatment prediction of sustained virological response (SVR) to peg-interferon plus ribavirin therapy in chronic hepatitis C...
  15. doi request reprint Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    J Hepatol 56:602-8. 2012
    ..We aimed to build a simple model for the identification of patients at high risk of developing HCC...
  16. ncbi request reprint Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy
    Kosei Hamano
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Japan
    J Gastroenterol Hepatol 20:1401-9. 2005
    ..However, mechanisms of the action of the combination regimen are not well understood. To elucidate the viral genetic basis of IFN plus RBV combination therapy, genetic variabilities of HCV-1b were analyzed...
  17. doi request reprint Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C
    Masayuki Kurosaki
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    J Med Virol 85:449-58. 2013
    ..In conclusion, a predictive model incorporating the ITPA genotype could identify patients with a high risk of anemia and reduced probability of sustained virological response...
  18. ncbi request reprint Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B
    Hiroyuki Nakanishi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Intervirology 48:381-8. 2005
    ..In conclusion, genotypic assays for the rt180M mutation after viral breakthrough may be useful in predicting the risk of breakthrough hepatitis and in deciding when to initiate alternative or additive nucleoside analogue therapy...
  19. doi request reprint Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm
    Kenichi Takayasu
    Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
    Liver Int 33:762-70. 2013
    ..To clarify the biological behaviour of small hypovascular hepatocellular carcinoma (HCC) because of insufficient evidence even though frequently encountered...
  20. doi request reprint Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Hepatology 52:518-27. 2010
    ..Hepatitis C viral eradication had a smaller effect on hepatocarcinogenesis in older patients. Patients should therefore be identified at an earlier age and treatment should be initiated...
  21. ncbi request reprint Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
    Kaoru Tsuchiya
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Cancer 120:229-37. 2014
    ..In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC...
  22. doi request reprint Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey
    Taku Aoki
    Hepato Biliary Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan Department of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan Department of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Izunokuni, Japan Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka Sayama, Japan Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan Department of Pathology, Keio University School of Medicine, Tokyo, Japan Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan Surgery, Japanese Red Cross Medical Center, Tokyo, Japan
    Ann Surg 259:532-42. 2014
    ..The aim of the present study was to investigate the background characteriscs of ruptured hepatocellular carcinoma (HCC) and to clarify the true impact of tumor rupture on patient prognosis in a large patient cohort...
  23. ncbi request reprint Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    J Hepatol 39:421-7. 2003
    ..To address the molecular mechanism for enhanced antiviral efficacy associated with a frequent dosing of interferon (IFN)-beta...
  24. ncbi request reprint [Combination therapy of interferon plus ribavirin for chronic hepatitis C]
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Rinsho 62:467-73. 2004
  25. ncbi request reprint Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Antivir Ther 16:685-94. 2011
    ..The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in combination with other factors...
  26. ncbi request reprint Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    J Hepatol 39:1063-9. 2003
    ..To clarify the factors associated with the efficacy of lamivudine...
  27. doi request reprint Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino shi, Tokyo, Japan
    J Hepatol 54:439-48. 2011
    ..Recent studies revealed an association between the IL28B genotype and treatment response. We aimed to develop a model for the pre-treatment prediction of response using host and viral factors...
  28. doi request reprint Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study
    Yutaka Yasui
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Oncology 86:53-62. 2014
    ..Our study aimed to elucidate the association between SLC22A7 expression and HCC development in chronic hepatitis C patients...
  29. doi request reprint Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Naoya Sakamoto
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
    J Med Virol 83:871-8. 2011
    ..In conclusion, IL-28B polymorphism affects responses to PEG-IFN-based treatment in difficult-to-treat HCV patients...
  30. ncbi request reprint [Epithelioid hemangioendothelioma of the liver diagnosed by laparoscopy guided biopsy]
    Nobutoshi Komatsu
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Shokakibyo Gakkai Zasshi 105:1640-7. 2008
    ..EHE tend to locate in peripheral and extend to the liver capsule. Therefore, we face difficulties in getting biopsy sample safely. Here we report a useful case of laparoscopic examination and biopsy in the diagnosis of EHE...
  31. pmc Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy
    Takanori Hosokawa
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180 8610, Japan
    World J Gastroenterol 19:249-57. 2013
    ..To evaluate whether metabolic factors are related to distant recurrence of hepatocellular carcinoma (HCC) and survival after curative treatment...
  32. ncbi request reprint [A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy]
    Yuji Kawano
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan
    Nihon Shokakibyo Gakkai Zasshi 110:1030-7. 2013
    ..Oral administration of melphalan and dexamethasone improved his clinical features and CT findings. We consider this case as rare in that the deposition of amyloid protein caused cholangiectasis...
  33. doi request reprint Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system
    Masatoshi Kudo
    Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Clin Drug Investig 32:37-51. 2012
    ..Sorafenib should currently not be used as adjuvant therapy or in combination with TACE or HAIC until evidence from ongoing clinical trials shows that it is beneficial in these settings...
  34. doi request reprint Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
    Kenichi Takayasu
    Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
    J Hepatol 56:886-92. 2012
    ..However, the best indication and appropriateness of the algorithm for TACE are still unclear...
  35. doi request reprint Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation
    Kaoru Tsuchiya
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    Oncology 80:278-88. 2011
    ..We investigated the clinical usefulness of K19 positivity in patients who had received curative radiofrequency ablation (RFA)...
  36. doi request reprint Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    J Med Virol 83:445-52. 2011
    ..A decision-tree model that includes these viral factors as predictors could identify patients with a high probability of sustained virological response...
  37. ncbi request reprint Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C
    Yasuhiro Asahina
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo, 180 8610, Japan
    J Gastroenterol 49:1152-62. 2014
    ..We aimed to clarify the association between single nucleotide polymorphism (SNP) located near interleukin 28B and hepatocellular carcinoma (HCC)...
  38. doi request reprint Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment
    Yasushi Tamura
    Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, 757 Asahimachi Dori 1 Bancho, Chuo Ku, Niigata, 951 8520, Japan
    Dig Dis Sci 58:2406-12. 2013
    ..Recently, a highly sensitive immunoassay using an on-chip electrokinetic reaction and separation by affinity electrophoresis (micro-total analysis system; μTAS) has been developed...
  39. doi request reprint Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy
    Jun Itakura
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan Abbott Molecular, Des Plaines, Illinois, USA
    Hepatol Res 41:217-24. 2011
    ..An early response reflects sensitivity to therapy, and the estimation of an undetectable time point would be useful for determining the optimal duration of treatment for chronic hepatitis C patients...
  40. ncbi request reprint Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy
    Masayuki Kurosaki
    Divisions of Gastroenterology and Hepatologym, Musashino Red Cross Hospital, Tokyo
    Hepatol Res 40:870-7. 2010
    ....
  41. doi request reprint Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma
    Teiji Kuzuya
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan
    Oncology 81:251-8. 2011
    ....
  42. doi request reprint Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy
    Taisuke Ueda
    Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Dig Dis 30:554-60. 2012
    ..However, more than half of the patients cannot achieve sustained viral response (SVR). In Japan, the clinical benefit of retreatment with PEG-IFN + RBV combination retreatment is still unknown...
  43. ncbi request reprint A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    Hepatol Res 40:251-60. 2010
    ....
  44. ncbi request reprint Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection
    Hideki Watanabe
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo, Japan 113 8519
    Virology 311:376-83. 2003
    ..In conclusion, our results strongly suggest that serum HCV RNA loads are inversely correlated with amino acid substitutions in the ISDR, and aa 962 was identified as a possible second determinant of serum HCV RNA load...
  45. ncbi request reprint [Analysis of replicating hepatitis C virus quasispecies in hepatocellular carcinoma tissues]
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Rinsho 62:624-8. 2004
  46. ncbi request reprint [How to use viral genomic analysis in clinical practice: chronic hepatitis B and C]
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino 180 8610
    Rinsho Byori 54:395-9. 2006
    ..When patients treated by combination therapy achieve a 2 log drop in HCV antigen until twelve weeks, they are estimated to have obtained 75% SVR by monitoring the amount of serum core antigen...
  47. ncbi request reprint [Present status of the treatment of chronic hepatitis C in Japan compared from Western countries]
    Namiki Izumi
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Shokakibyo Gakkai Zasshi 101:585-90. 2004
  48. ncbi request reprint Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells
    Yuka Miyasaka
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
    J Infect Dis 188:1537-44. 2003
    ..These findings suggest that the NS5A protein inhibits the apoptotic effect of TNF-alpha upstream of caspase-8 in the apoptosis cascade...
  49. ncbi request reprint Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashinoshi, Tokyo, Japan
    Hepatol Res 37:S254-63. 2007
    ..It is a point of controversy when liver transplantation should be recommended in HCC patients with liver cirrhosis of Child-Pugh A classification having chronic HCV infection because of the high incidence of recurrence...
  50. ncbi request reprint [Hepatitis B viral mutation and its clinical significance]
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Rinsho 62:167-74. 2004
  51. ncbi request reprint Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease
    Hideki Watanabe
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo, Tokyo 113 8519, Japan
    J Gen Virol 84:3275-89. 2003
    ..These data indicate the existence of a genetic subgroup of HDV genotype IIb, which is associated with different clinical characteristics and which could be related to genetic variations in functionally important parts of the HDV genome...
  52. ncbi request reprint [Prevention of adverse effects in ribavirin and interferon combination therapy]
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Rinsho 62:523-7. 2004
  53. doi request reprint The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy
    Masayuki Kurosaki
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo, Japan
    J Hepatol 48:736-42. 2008
    ..The aim of the present study was to define factors associated with progression of fibrosis in patients who do not achieve a SVR...
  54. ncbi request reprint [Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma]
    Kaoru Tsuchiya
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Shokakibyo Gakkai Zasshi 105:808-16. 2008
  55. ncbi request reprint Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan
    Masatoshi Kudo
    Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osakasayama, Osaka, Japan
    Oncology 84:21-7. 2013
    ..Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups...
  56. doi request reprint Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers
    Yukio Osaki
    Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
    J Gastroenterol 48:874-83. 2013
    ..This study was conducted to evaluate the efficacy and safety of a bipolar RFA device (CelonPOWER System) in the treatment of Japanese liver cancer patients...
  57. ncbi request reprint Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study
    Naoshi Horikawa
    Department of Psychiatry, Tokyo Women s Medical University, Tokyo, Japan
    Gen Hosp Psychiatry 25:34-8. 2003
    ..Such patients require careful observation, and psychiatrists should be sufficiently aware of this significant psychiatric complication of interferon therapy...
  58. doi request reprint Laparoscopic radiofrequency ablation for hepatocellular carcinoma
    Yasuhiro Asahina
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino shi, Tokyo, Japan
    Dig Endosc 21:67-72. 2009
    ..Recent advances in laparoscopic ultrasound have widened the indication for laparoscopic ablation. In the present paper, we review the indications, advantages, prognosis and safety of laparoscopic RFA for hepatocellular carcinoma...
  59. doi request reprint Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model
    Jun Itakura
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1 26 1 Kyonan cho, Musashino shi, Tokyo 180 8610, Japan
    Biosystems 99:70-8. 2010
    ..These agent-based simulation models reproducibly provide a visual representation of the disease, and enable a simulation that encompasses parameters those are difficult to account for in a mathematical model...
  60. doi request reprint Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Kyonancho, Musashinoshi, Tokyo, Japan nizumi musashino jrc or jp
    Oncology 78:78-86. 2010
    ..At the joint symposium with JSH and the International Liver Cancer Association (ILCA), the algorithm of diagnosis and treatment for HCC was discussed using Answerpad. Several important discussions are described in this article...
  61. doi request reprint Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatol Res 43:596-604. 2013
    ..In order to evaluate and judge a fibrotic stage of patients with chronic hepatitis B, multivariate regression analysis was performed using multiple fibrosis markers...
  62. ncbi request reprint [Ulcerative colitis developed after acute exacerbation of chronic hepatitis B]
    Nobuhiko Kanazawa
    Divisions of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo
    Nihon Naika Gakkai Zasshi 91:2192-5. 2002
  63. pmc No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations
    Hiromi Sawai
    Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033, Japan
    BMC Med Genet 13:47. 2012
    ....
  64. ncbi request reprint Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan
    Sumio Watanabe
    Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
    Hepatol Res 40:135-44. 2010
    ..2%). Conclusions: Patients with CHCV genotype 1 infection should be treated with PEG-IFN plus ribavirin combination therapy as early as possible, and 72 weeks' treatment is recommended in patients with LVR regardless of age...
  65. pmc New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia
    Nao Nishida
    The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    PLoS ONE 9:e86449. 2014
    ..The present findings will serve as a base for future functional studies of HLA-DP molecules in order to understand the pathogenesis of HBV infection and the development of hepatocellular carcinoma. ..
  66. ncbi request reprint [High-sensitivity C-reactive protein (hs-CRP): a promising biomarker for the screening of non-alcoholic steatohepatitis (NASH)]
    Masakatsu Uchihara
    Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
    Nihon Rinsho 64:1133-8. 2006
    ..hs-CRP may be a promising biomarker for screening of NASH, a hepatic manifestation of metabolic syndrome...
  67. doi request reprint Recent advances of radiofrequency ablation for early hepatocellular carcinoma
    Namiki Izumi
    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 26:115-22. 2011
    ..Overall survival after between RFA and surgical resection should be compared prospectively. Establishment of staging system for treatment allocation of HCC and prevention of HCC recurrence is important issue to be examined...
  68. doi request reprint Liver Cancer Working Group report
    Masatoshi Kudo
    Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377 2, Ohono Higashi, Osaka Sayama, Osaka, Japan
    Jpn J Clin Oncol 40:i19-27. 2010
    ..Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation...
  69. doi request reprint Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
    Haruhiko Yoshida
    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, and Department of Gastroenterology and Hepatology, Kanto Central Hospital, Tokyo, Japan
    Hepatology 54:532-40. 2011
    ..150 (95% confidence interval: 0.843-1.570, one-sided; P=0.811) between the placebo and combined active-drug groups, and the study was discontinued in March 2007...